Article
Medicine, General & Internal
Alice Burgevin, Benedicte Caron, Alexa Sasson, Amandine Luc, Patrick Netter, Cedric Baumann, Ashwin N. Ananthakrishnan, Laurent Peyrin-Biroulet
Summary: The safety of vedolizumab and ustekinumab therapies in older patients with inflammatory bowel disease was compared. The study found that there was no difference in terms of safety between vedolizumab and ustekinumab in patients with Crohn's disease. The occurrence of adverse events per year of follow-up was also similar between vedolizumab and anti-TNF therapy for ulcerative colitis and Crohn's disease.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Daniela Pugliese, Giuseppe Privitera, Federica Crispino, Nicolo Mezzina, Fabiana Castiglione, Gionata Fiorino, Lucrezia Laterza, Anna Viola, Lorenzo Bertani, Flavio Caprioli, Maria Cappello, Brigida Barberio, Chiara Ricci, Paola Balestrieri, Marco Daperno, Dario Pluchino, Fernando Rizzello, Maria Lia Scribano, Renato Sablich, Luca Pastorelli, Francesco Manguso, Angela Variola, Antonio Di Sario, Laurino Grossi, Alessandro Armuzzi
Summary: The study included 198 elderly (108 UC, 90 CD) and 396 matched nonelderly patients (205 UC, 191 CD). Nonelderly UC patients had a significantly higher persistence on vedolizumab compared to elderly patients. No significant difference in effectiveness was observed between elderly and nonelderly CD patients.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Gastroenterology & Hepatology
Ohad Atia, Sasha Harel, Natan Ledderman, Shira Greenfeld, Revital Kariv, Iris Dotan, Ran Balicer, Barbara Silverman, Eran Matz, Zohar Levi, Matti Waterman, Iris Fried, Jacob M. Rowe, Dan Turner
Summary: Pediatric onset inflammatory bowel disease (PIBD) patients have a higher risk of developing cancer compared to non-inflammatory bowel disease (IBD) children, but the absolute risk is very low, and no significant differences in risk were found among different treatment methods in our data.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Immunology
Yiyoung Kwon, Yoon Zi Kim, Yon Ho Choe, Mi Jin Kim
Summary: This study found that patients with high monocyte counts at the time of discontinuation were more likely to experience relapse after stopping biologics. The monocyte percentage can be used to predict the risk of relapse within 6 months after discontinuation.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Gastroenterology & Hepatology
Ole Haagen Nielsen, John Mark Gubatan, Carsten Bogh Juhl, Sarah Elizabeth Streett, Cynthia Maxwell
Summary: Adverse pregnancy outcomes among pregnant IBD women using biologics are comparable with that of the general population.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Pediatrics
So Yoon Choi, Ben Kang
Summary: The introduction of biological agents, particularly anti-TNF agents, has significantly improved the long-term prognosis of patients with inflammatory bowel disease (IBD). In pediatric populations, only two biological agents, infliximab (IFX) and adalimumab (ADL), have been approved for use. ADL has shown efficacy in achieving mucosal healing (MH) and histological remission in both naive patients and those who have previously received biologic treatment. Therapeutic drug monitoring may further enhance the effectiveness of ADL treatment and reduce treatment failure.
FRONTIERS IN PEDIATRICS
(2022)
Article
Gastroenterology & Hepatology
Motasem Alkhayyat, Mohammad Abureesh, Ashraf Almomani, Mohannad Abou Saleh, Mohammad Zmaili, Sara El Ouali, Emad Mansoor, Alberto Rubio-Tapia, Miguel Regueiro
Summary: In this study, a large database was used to explore the association between celiac disease and inflammatory bowel disease (IBD) and the impact of IBD treatment. The results showed a bidirectional association between celiac disease and IBD, with a stronger association observed in Crohn's disease (CD). Patients with IBD who received corticosteroids, 5-aminosalicylates, immunomodulators, or anti-tumor necrosis factor drugs had a lower association with celiac disease. Additional research is needed to understand the underlying mechanisms for the modification of celiac disease incidence by IBD therapy.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Kengo Kanayama, Jun Kato, Wataru Shiratori, Ariki Nagashima, Yuki Ohta, Takashi Taida, Keiko Saito, Chihiro Goto, Satsuki Takahashi, Ryosuke Horio, Akane Kurosugi, Tsubasa Ishikawa, Tatsuya Kaneko, Naoki Akizue, Kenichiro Okimoto, Tomoaki Matsumura, Naoya Kato
Summary: This study found that selecting subsequent treatment based on the response to initial anti-tumor necrosis factor (TNF)alpha antibody (ATA) is feasible in refractory ulcerative colitis (UC) patients. Non-ATA may be suitable as subsequent biologics for UC patients regardless of the efficacy of the first ATA.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Pharmacology & Pharmacy
Mengyao Wang, Jingwen Zhao, Heran Wang, Changqing Zheng, Bing Chang, Lixuan Sang
Summary: This study evaluated the efficacy of methotrexate in patients with Crohn's disease and ulcerative colitis, and identified predictors of surgery for patients initially treated with methotrexate monotherapy. The study analyzed a large cohort of patients with inflammatory bowel disease and used logistic regression and nomograms to identify factors associated with methotrexate efficacy. The findings demonstrated good predictive accuracy and agreement with actual observations.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Gastroenterology & Hepatology
Ruby Greywoode, Francesca Petralia, Thomas A. Ullman, Jean Frederic Colombel, Ryan C. Ungaro
Summary: Racial minority groups showed lower rates of clinical response, clinical remission, and endoscopic healing in golimumab induction and maintenance trials compared to White participants.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Medicine, General & Internal
Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Eirini Theodoraki, Ioannis E. Koutroubakis
Summary: Despite advancements in inflammatory bowel disease (IBD) management, anti-TNF agents continue to be the primary treatment for Crohn's disease and ulcerative colitis. However, optimizing treatment strategies is essential due to the progressive nature of the disease and potential loss of response. This overview examines the role of therapeutic drug monitoring (TDM), combining anti-TNF with immunomodulators, and the treat-to-target approach in enhancing the efficacy and outcomes of anti-TNF treatment.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Lorenzo Bertani, Brigida Barberio, Domenico Trico, Federico Zanzi, Daria Maniero, Linda Ceccarelli, Ilaria Marsilio, Francesca Coppini, Greta Lorenzon, Maria Gloria Mumolo, Fabiana Zingone, Francesco Costa, Edoardo Vincenzo Savarino
Summary: The study found that hospitalization for intravenous biologics treatment did not increase the risk of COVID-19 infection in patients with inflammatory bowel diseases during the COVID-19 outbreak. Additionally, there was a similar level of anxiety between patients receiving intravenous and subcutaneous drug treatments.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Biochemistry & Molecular Biology
Monica State, Lucian Negreanu
Summary: There is a lack of clear definitions and guidelines for the response criteria and treatment optimization in advanced therapies for inflammatory bowel disease, leading to inconsistent treatment strategies and premature abandonment of effective therapies.
Article
Gastroenterology & Hepatology
Ryo Seishima, Koji Okabayashi, Hiroki Ikeuchi, Motoi Uchino, Kitaro Futami, Tatsuki Noguchi, Hiroki Ohge, Yasuhito Iseki, Kazuhiro Watanabe, Michio Itabashi, Kinya Okamoto, Yuji Toiyama, Takayuki Ogino, Masafumi Nakamura, Kazutaka Yamada, Toshifumi Wakai, Yu Sato, Hideaki Kimura, Kenichi Takahashi, Koya Hida, Yusuke Kinugasa, Fumio Ishida, Junji Okuda, Koji Daito, Fumikazu Koyama, Hideki Ueno, Takayuki Yamamoto, Seiichiro Yamamoto, Tsunekazu Hanai, Atsuo Maemoto, Junya Arakaki, Koji Komori, Yoshito Akagi, Dai Shida, Shigeki Yamaguchi, Keiji Matsuda, Kiyoshi Maeda, Toshihiro Noake, Riichiro Nezu, Shin Sasaki, Junichi Hasegawa, Eiji Sunami, Yukihide Kanemitsu, Kenji Katsumata, Kei Uehara, Tomomichi Kiyomatsu, Takeshi Suto, Shinsuke Kazama, Takeshi Yamada, Takenori Goi, Soichiro Ishihara, Yoichi Ajioka, Kenichi Sugihara
Summary: This study aimed to evaluate the impact of biologics on the risk of advanced-stage inflammatory bowel disease (IBD)-associated intestinal cancer. The results showed that in patients with Crohn's disease (CD), no drugs were significantly associated with cancer stage. However, in patients with ulcerative colitis (UC), less use of biologics, 5-aminosalicylic acid, and immunomodulators was significantly associated with advanced cancer stage. Multivariate analysis demonstrated that biologic use was significantly associated with a lower risk of advanced-stage disease.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Neasa Mc Gettigan, Aman Shah Afridi, Grace Harkin, Caroline Lardner, Stephen Patchett, Danny Cheriyan, Gavin Harewood, Karen Boland, Aoibhlinn O'Toole
Summary: The study aimed to identify optimal management strategies for anti-drug antibodies (ADAs) in patients receiving infliximab (IFX) to prevent therapy discontinuation. Results showed that increasing IFX dosage and adjusting combination therapy can lower rates of discontinuation of IFX, with significant cut-off values for ADA trough levels and important clinical outcomes identified through ROC curve analysis.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2021)
Article
Oncology
Osman Oecal, Daniel Roessler, Antonio Gasbarrini, Thomas Berg, Heinz-Josef Klumpen, Irene Bargellini, Bora Peynircioglu, Otto van Delden, Christian Schulz, Kerstin Schuette, Roberto Iezzi, Maciej Pech, Peter Malfertheiner, Bruno Sangro, Jens Ricke, Max Seidensticker
Summary: This study evaluated the prognostic value of gadoxetic acid uptake on hepatobiliary phase MRI in advanced HCC patients receiving sorafenib. High gadoxetic acid uptake was associated with shorter survival, highlighting its potential role in treatment decision-making.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Gastroenterology & Hepatology
Chen Sarbagili Shabat, Franco Scaldaferri, Eran Zittan, Ayal Hirsch, Maria Chiara Mentella, Tania Musca, Nathaniel Aviv Cohen, Yulia Ron, Naomi Fliss Isakov, Jorge Pfeffer, Michal Yaakov, Caterina Fanali, Laura Turchini, Luca Masucci, Gianluca Quaranta, Nitzan Kolonimos, Anastasia Godneva, Adina Weinberger, Uri Kopylov, Arie Levine, Nitsan Maharshak
Summary: This study evaluated the impact of novel diets and fecal transplantation on the remission rate of refractory ulcerative colitis. The results suggest that using the UC Exclusion Diet alone may be more effective in achieving clinical remission and mucosal healing compared to single donor FT or no donor diet.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Acoustics
Matteo Garcovich, Mariella Faccia, Enrico Di Stasio, Laura Riccardi, Maria A. Zocco, Maria E. Ainora, Fabio M. Vecchio, Geltrude Mingrone, Antonio Gasbarrini, Maurizio Pompili
Summary: The study investigated the agreement between different equipment for liver stiffness quantification, showing a very good correlation between QElaXto techniques and SSI in LS measurements. Cut-off thresholds for fibrosis staging in non-HBV-related CLD were identified using two QElaXto techniques for the first time.
JOURNAL OF ULTRASOUND IN MEDICINE
(2022)
Review
Biotechnology & Applied Microbiology
Stefano Bibbo, Gianluca Ianiro, Federica Giambo, Carlo Romano Settanni, Giovanni Cammarota, Antonio Gasbarrini
Summary: The gut microbiota plays a crucial role in cancer pathophysiology and therapy response. Studies have shown that modulation of the microbiota can help predict and improve the response to immunotherapy, with promising results particularly in melanoma research.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Gastroenterology & Hepatology
Alessandro Vitale, Gianluca Svegliati-Baroni, Alessio Ortolani, Monica Cucco, Giulio Dalla Riva, Edoardo G. Giannini, Fabio Piscaglia, Gianludovico Rapaccini, Mariella Di Marco, Eugenio Caturelli, Marco Zoli, Rodolfo Sacco, Giuseppe Cabibbo, Fabio Marra, Andrea Mega, Filomena Morisco, Antonio Gasbarrini, Francesco Giuseppe Foschi, Gabriele Missale, Alberto Masotto, Gerardo Nardone, Giovanni Raimondo, Francesco Azzaroli, Gianpaolo Vidili, Filippo Oliveri, Filippo Pelizzaro, Rafael Ramirez Morales, Umberto Cillo, Franco Trevisani, Luca Miele, Giulio Marchesini, Fabio Farinati
Summary: This study compared patients with MAFLD and non-MAFLD who had hepatocellular carcinoma (HCC) in Italy. It found that the proportion of MAFLD in HCC patients was increasing over time and is expected to surpass non-MAFLD in the future. Despite a later cancer stage at diagnosis, MAFLD HCC patients had a lower risk of HCC-related death, suggesting reduced cancer aggressiveness.
Review
Oncology
Mariella Faccia, Matteo Garcovich, Maria Elena Ainora, Laura Riccardi, Maurizio Pompili, Antonio Gasbarrini, Maria Assunta Zocco
Summary: The evaluation of tumor response to anti-cancer therapy is critical in oncology for treatment planning and follow-up strategies. Contrast-enhanced ultrasound (CEUS) and dynamic CEUS are promising tools for early tumor response evaluation. This article provides a general review of the usefulness of CEUS in monitoring HCC response to therapy, highlighting its role in different disease stages.
Article
Microbiology
Pauline Raoul, Marco Cintoni, Marta Palombaro, Luisa Basso, Emanuele Rinninella, Antonio Gasbarrini, Maria Cristina Mele
Summary: Diet is a crucial factor in causing and treating inflammatory bowel disease (IBD). Food additives, such as artificial emulsifiers and sweeteners, can disrupt the gut microbiota and lead to chronic inflammation in the intestines, accelerating the onset of IBD. While more research is needed, it is advisable for IBD patients to avoid processed foods containing artificial food additives.
Article
Gastroenterology & Hepatology
Filippo Pelizzaro, Giulia Peserico, Marco D'Elia, Nora Cazzagon, Francesco Paolo Russo, Alessandro Vitale, Edoardo G. Giannini, Manuela Piccinnu, Gian Ludovico Rapaccini, Maria Di Marco, Eugenio Caturelli, Marco Zoli, Rodolfo Sacco, Giuseppe Cabibbo, Fabio Marra, Andrea Mega, Filomena Morisco, Antonio Gasbarrini, Gianluca Svegliati-Baroni, Francesco Giuseppe Foschi, Andrea Olivani, Alberto Masotto, Gerardo Nardone, Giovanni Raimondo, Francesco Azzaroli, Gianpaolo Vidili, Filippo Oliveri, Franco Trevisani, Fabio Farinati
Summary: Increasing the surveillance interval from 3 to 6 months for cirrhotic patients with viral etiology did not result in a reduction of patients diagnosed at advanced cancer stages or an increase in the likelihood of receiving curative treatments.
DIGESTIVE AND LIVER DISEASE
(2022)
Article
Medicine, General & Internal
Lucrezia Laterza, Marco Napoli, Valentina Petito, Franco Scaldaferri, Eleonora Gaetani, Antonio Gasbarrini
Summary: This study evaluated the adherence to probiotic therapy in real-life and identified factors that influenced adherence. It found that 60% of patients took all the prescribed probiotic therapy and perceived benefits in more than 60% of cases. The main factors affecting adherence were the price of the product, mild adverse events, and poor appreciation of flavor.
Article
Medicine, General & Internal
Olga Maria Nardone, Giovanni Marasco, Loris Riccardo Lopetuso, Giammarco Mocci, Luca Pastorelli, Carlo Petruzzellis, Franco Scaldaferri
Summary: This study investigated the use of mesalazine in the clinical practice of young gastroenterologists. The results showed that there were significant differences in the use of mesalazine between non-dedicated and IBD physicians, especially in the management of moderate-severe ulcerative colitis. It was also observed that non-IBD physicians were less likely to prescribe mesalazine for colorectal cancer chemoprevention.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Oncology
Valerio Papa, Tommaso Schepis, Gaetano Coppola, Michele Francesco Chiappetta, Livio Enrico Del Vecchio, Tommaso Rozera, Giuseppe Quero, Antonio Gasbarrini, Sergio Alfieri, Alfredo Papa
Summary: Pancreatic cancer is a difficult-to-treat disease, and exploring the role of microbiota in its development and treatment holds promise for improving outcomes. The gut, pancreatic, and oral microbiota have been shown to play a role in the pathogenesis of pancreatic cancer, and changes in these microbiota can potentially be used for early diagnosis and predicting treatment response. Further research is needed to increase the available data in this promising area.
Review
Gastroenterology & Hepatology
Angelo Del Gaudio, Federica Di Vincenzo, Valentina Petito, Maria Cristina Giustiniani, Antonio Gasbarrini, Franco Scaldaferri, Loris Riccardo Lopetuso
Summary: Immune-related adverse events (IRAEs) are a significant side effect arising from the use of immune checkpoint inhibitors (ICIs), with checkpoint inhibitor colitis being the most widely reported IRAE. This review comprehensively discusses the current evidence regarding the pathogenesis, diagnosis, and management of ICIs-induced colitis, including innovative therapies.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Medicine, General & Internal
Irene Mignini, Rossella Maresca, Maria Elena Ainora, Luigi Larosa, Franco Scaldaferri, Antonio Gasbarrini, Maria Assunta Zocco
Summary: Therapeutic options for IBD have expanded, but choosing the best treatment for each patient is still a challenge. Early prediction of response to biological drugs is important for optimizing therapeutic strategies. Recent research has focused on imaging techniques to identify predictive markers of response to biologic therapies.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Cell Biology
Federica Di Vincenzo, Ylenia Yadid, Valentina Petito, Valeria Emoli, Letizia Masi, Daniela Gerovska, Marcos Jesus Arauzo-Bravo, Antonio Gasbarrini, Birgitte Regenberg, Franco Scaldaferri
Summary: Inflammatory bowel diseases (IBD), including Crohn's Disease (CD) and Ulcerative Colitis (UC), are chronic disorders affecting the gastrointestinal tract. The etiology and pathogenesis of IBD are still unknown, but recent studies suggest a potential role of cell-free DNAs (cfDNAs) and extrachromosomal circular DNA (eccDNA) in IBD. This review aims to collect and summarize available knowledge on cfDNAs, eccDNA, and their involvement in the pathogenesis of IBD. Potential molecular therapies and drug delivery systems for IBD treatment, such as nanoparticles, are also discussed.
Article
Microbiology
Loris Riccardo Lopetuso, Lucrezia Laterza, Valentina Petito, Silvia Pecere, Gianluca Quaranta, Federica Del Chierico, Pierluigi Puca, Elisa Schiavoni, Daniele Napolitano, Andrea Poscia, Gianluca Ianiro, Daniela Pugliese, Lorenza Putignani, Maurizio Sanguinetti, Alessandro Armuzzi, Luca Masucci, Antonio Gasbarrini, Giovanni Cammarota, Franco Scaldaferri
Summary: This study aimed to evaluate the effectiveness of exercise therapy for patients with cervical spondylosis. The results showed that patients who received exercise therapy had significantly better pain levels, functional recovery, and quality of life compared to those who received traditional treatment.